Maravai Lifesciences Holdings (MRVI) Gross Margin (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) posted quarterly Gross Margin of 51.19% for Q1 2026, up 3470.0% year-over-year from 1.43% in Q1 2025, and up 98.77% quarter-over-quarter from 25.75% in Q4 2025.
Powered by 
Analysis
Maravai Lifesciences Holdings (MRVI) Gross Margin (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' Gross Margin history runs 7 years deep, the most recent figure standing at 51.19% for Q1 2026.
- In Q1 2026, Gross Margin rose 3470.0% year-over-year to 51.19%; the TTM figure through Mar 2026 stood at 29.29% (down 800.0% YoY), while the FY2025 annual figure was 18.3%, down 2349.0% from the prior year.
- Gross Margin for Q1 2026 stood at 51.19%, up from 25.75% in the prior quarter.
- The five-year high for Gross Margin was 84.55% in Q2 2022, with the low at 13.58% in Q3 2025.
- The 5-year median for Gross Margin is 45.13% (2023), against an average of 47.27%.
- The sharpest annual moves came in 2023 and 2026: Gross Margin sank 4735 bps in 2023, then soared 3470 bps in 2026.
- Maravai Lifesciences Holdings' Gross Margin stood at 73.99% in 2022, then dropped by 29 bps to 52.65% in 2023, then plunged by 35 bps to 34.28% in 2024, then dropped by 25 bps to 25.75% in 2025, then surged by 99 bps to 51.19% in 2026.
- Business Quant data shows MRVI's Gross Margin at 51.19% in Q1 2026, 25.75% in Q4 2025, and 13.58% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | Maravai Lifesciences Holdings | 1.09 Bn | 1.02 Bn | 20.65 Mn | 40.14% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 40.14% |
| Mar 31, 2026 | 51.19% |
| Dec 31, 2025 | 25.75% |
| Sep 30, 2025 | 13.58% |
| Jun 30, 2025 | 16.39% |
| Mar 31, 2025 | 16.49% |
| Dec 31, 2024 | 34.28% |
| Sep 30, 2024 | 46.70% |
| Jun 30, 2024 | 44.42% |
| Mar 31, 2024 | 40.27% |
| Dec 31, 2023 | 52.65% |
| Sep 30, 2023 | 45.13% |
| Jun 30, 2023 | 37.21% |
| Mar 31, 2023 | 57.39% |
| Dec 31, 2022 | 73.99% |
| Sep 30, 2022 | 80.04% |
| Jun 30, 2022 | 84.55% |
| Mar 31, 2022 | 83.61% |
| Dec 31, 2021 | 82.87% |
| Sep 30, 2021 | 84.27% |